Bern, Berne, Switzerland
I design and scale robust downstream processes that make plasmaderived proteins and recombinant proteins (fusion proteins & mAbs) reproducible, compliant, and commercialready. With 15+ years in Bioprocess Development (CMC), I lead crossfunctional global teams and turn complex technical programs into measurable outcomes. Signature results include a +10% yield improvement in CSL’s IgPro process (Privigen®/Hizentra®) and the implementation of an isoagglutininremoval step to strengthen product safety. I also led Phase III/commercial process development for Garadacimab (mAb) and built predictive scaledown models used across multiple assets and sites. My core strengths span Downstream processing, Scaledown & scaleup, Tech transfer (internal & external), site comparability, deviation investigations, process characterization, facility fit, and regulatory authoring (IND/BLA). I’m comfortable partnering with QA/Manufacturing, Research, and external CMOs to drive lifecycle improvements and resolve critical deviations under tight timelines. Current focus: advancing an ethanolfree, lowOPEX, highyield downstream process for human Albumin, integrating rigorous comparability and validation principles to ensure developability and commercial readiness. If you’re working on CMC strategy, yield optimization, scaledown model fidelity, tech transfers, or regulatory readiness, let’s connect—I enjoy swapping lessons learned and collaborating on approaches that make biologics safer, more robust, and simpler to manufacture.
u.a. Personalführung, Projektverantwortung, Prozessentwicklung, Evaluierung und Etablierung neuer Technologien sowie Vertretung der Abteilung in globalen Projektteams